

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org/) on May 17, 2025

MDA-MB-134-VI

RRID:CVCL_0617

Type: Cell Line

Proper Citation

(RRID:CVCL_0617)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0617

Proper Citation: (RRID:CVCL_0617)

Sex: Female

Defining Citation: [PMID:730202](#), [PMID:833871](#), [PMID:3518877](#), [PMID:4412247](#), [PMID:6220172](#), [PMID:7842014](#), [PMID:9331070](#), [PMID:9671407](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:11343771](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24425047](#), [PMID:25485619](#), [PMID:25757734](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28889351](#), [PMID:30228172](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: DNA methylation analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: ICBP43 breast cancer cell line panel., Part of: JWGray breast cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: MDA-MB-134-VI

Synonyms: MDA-MB-134 VI, MDA MB 134VI, MDA-MB-134VI, MDAMB134VI, MDA-MB-

134, MDAMB134, MDA-134, MDA134, MM134, MD Anderson-Metastatic Breast-134-VI

Cross References: CLO:CLO_0007631, EFO:EFO_0001205, CLDB:cl3398, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:HTB-23, BioSample:SAMN03471473, BioSample:SAMN10988465, cancercellines:CVCL_0617, CCRID:1101HUM-PUMC000380, Cell_Model_Passport:SIDM00005, ChEMBL-Cells:ChEMBL3308340, ChEMBL-Targets:ChEMBL2366242, Cosmic:687491, Cosmic:735125, Cosmic:809233, Cosmic:904374, Cosmic:908119, Cosmic:934525, Cosmic:997933, Cosmic:1000129, Cosmic:1046947, Cosmic:1047696, Cosmic:1090333, Cosmic:1136347, Cosmic:1152519, Cosmic:1287908, Cosmic:1289392, Cosmic:1603216, DepMap:ACH-000044, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908119, GEO:GSM115107, GEO:GSM186432, GEO:GSM186433, GEO:GSM186434, GEO:GSM217584, GEO:GSM219959, GEO:GSM320180, GEO:GSM350523, GEO:GSM421870, GEO:GSM783960, GEO:GSM847398, GEO:GSM847491, GEO:GSM887292, GEO:GSM888367, GEO:GSM1053695, GEO:GSM1172976, GEO:GSM1172886, GEO:GSM1215268, GEO:GSM1226522, GEO:GSM1226523, GEO:GSM1226524, GEO:GSM1226525, GEO:GSM1226526, GEO:GSM1226527, GEO:GSM1226528, GEO:GSM1226529, GEO:GSM1226530, GEO:GSM1226531, GEO:GSM1226532, GEO:GSM1226533, GEO:GSM1226534, GEO:GSM1226535, GEO:GSM1226536, GEO:GSM1226537, GEO:GSM1226538, GEO:GSM1226539, GEO:GSM1226540, GEO:GSM1226541, GEO:GSM1238133, GEO:GSM1374647, GEO:GSM1401662, GEO:GSM1661981, GEO:GSM1670078, IARC_TP53:18375, IZSLER:BS TCL 236, LiGeA:CCLE_784, LINCS_HMS:50327, LINCS_LDP:LCL-1316, PharmacDB:MDAMB134VI_897_2019, Progenetix:CVCL_0617, PubChem_Cell_line:CVCL_0617, SLKBase:3582, Wikidata:Q54904577

ID: CVCL_0617

Record Creation Time: 20250131T201333+0000

Record Last Update: 20250131T202932+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-134-VI.

No alerts have been found for MDA-MB-134-VI.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://www.fdi-lab.com/sci-crunch.org).

Young TA, et al. (2024) Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma. *bioRxiv : the preprint server for biology*.

Yates ME, et al. (2024) ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. *Endocrinology*, 165(10).

Sottnik JL, et al. (2024) WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. *Cancer research communications*, 4(1), 134.

Olukoya AO, et al. (2023) Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. *Journal of the Endocrine Society*, 7(10), bvad117.

Yates ME, et al. (2023) ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes. *bioRxiv : the preprint server for biology*.

Elangovan A, et al. (2022) Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. *Molecular cancer research : MCR*, 20(9), 1405.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Chen F, et al. (2021) Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. *Cancer research*, 81(2), 268.

Sottnik JL, et al. (2021) Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. *Molecular cancer research : MCR*, 19(8), 1270.

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. *Cell*, 181(7), 1596.

Mabe NW, et al. (2020) G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. *Cell reports*, 33(5), 108341.

Sreekumar S, et al. (2020) Differential Regulation and Targeting of Estrogen Receptor ? Turnover in Invasive Lobular Breast Carcinoma. *Endocrinology*, 161(9).

Cotul EK, et al. (2020) Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. *Cancers*, 12(9).

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Guan J, et al. (2019) Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. *Cell*, 178(4), 949.